As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
HOME > ORGANIZATION
ORGANIZATION
- Price Band Rule Raising Prices of Rock-Bottom Generics: Sawai President
May 24, 2017
- Japan Biosimilar Association Says “Authorized Biosimilars” Could Mar Industry Development
May 17, 2017
- Market Price Survey for Off-Year Revision Should “Cover All Products”: JPWA
May 15, 2017
- JGA’s 1st Industry Vision Envisages Consolidation into 4 Biz Models
May 8, 2017
- JPMA to Draw Up Proposals on Continuous Manufacturing: Quality & Technology Committee
April 27, 2017
- JPMA to Focus on New Developments Including GCP Reform in FY2017: Drug Evaluation Committee
April 27, 2017
- Broader Approach to HTA Could Be Used to Validate Initial Pricing Premiums: PhRMA HTA Chief
April 26, 2017
- JPMA to Focus on Initiative to Reflect Post-Marketing Evidence for Efficacy in Package Inserts
April 26, 2017
- JPMA Says Bayer Rep Contacted It Last July over Xarelto Survey, Issue Should Be First Handled by Regulators
April 24, 2017
- PhRMA Submits Paper to Lawmaker Group, Demands Price Maintenance for On-Patent Drugs
April 21, 2017
- Innovation Premium Top Priority for 3 Trade Groups; EFPIA Ideally Wants Its Expansion
April 20, 2017
- Masaru Nakamura Resigns as Chairman of NPhA in Wake of False Claim Scandal Involving Qol
April 18, 2017
- PhRMA Chair Repeats Call for Keeping Price Maintenance Premium to Secure Market Predictability
April 13, 2017
- JGA Fires Back at Criticism on “Excessive” and “Expensive” Generics, Says No. of Makers Not So Many
April 11, 2017
- Asian Industry Groups Promote Collaboration to Discover Drugs from Natural Resources by Leveraging Asia’s Diverse Ecosystems
April 10, 2017
- JPMA to Support Japanese Drug Makers’ Overseas Expansion through Public-Private Cooperation
April 10, 2017
- Tap Tax Cuts and AMED Subsidies, not Price Premium, to Fuel Innovation: JMA Chief
April 7, 2017
- 26 Japan CRO Association Members Enjoy 12.7% Sales Jump in 2016
April 6, 2017
- Kampo Study Group Submits Proposal to LDP Lawmakers, Cites “Concerns About Stable Supply at Current NHI Prices”
April 6, 2017
- 3 Groups Lay Out Guidelines on Inter-Pharmacy Drug Transactions after Harvoni Flub
April 4, 2017
ページ
While grappling with sluggish revenues in Japan last year amid 1.7% negative market growth as put by IQVIA, mega pharma companies saw their upbeat oncology franchises increasingly buttress their businesses in the country, helping them soften the blows from generic…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…